Pasireotide: A novel treatment for patients with acromegaly

Chemical Compounds

• Pasireotide 100%
• Somatostatin 52%
• Octreotide 36%
• Ligand 16%
• Lanreotide 14%
• Hormone Receptor Blocking Agent 14%
• Glycemic 12%
• Growth Hormone 9%
• Dose 5%
• Glucose 5%
• Drug 4%

Medicine & Life Sciences

• pasireotide 77%
• Acromegaly 57%
• Somatostatin Receptors 18%
• Octreotide 13%
• Ligands 12%
• Therapeutics 7%
• Hyperglycemia 6%
• pegvisomant 5%
• lanreotide 5%
• Somatotropin Receptors 4%
• Hormone Antagonists 4%
• Phase III Clinical Trials 4%
• Somatomedins 3%
• Somatostatin 3%
• Combination Drug Therapy 3%
• Mortality 3%
• United States Food and Drug Administration 3%
• Diabetes Mellitus 2%
• Medicine 2%
• Glucose 2%
• Morbidity 2%
• Population 1%
• Neoplasms 1%